Breadcrumb

[A11-19] Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2011-10-05 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 62 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A12-11] Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2012-01-02 Extract of dossier assessment 62 kBPDFdownload file
2012-01-02 Dossier assessment (German version) 236 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of the dossier assessment

  File-Icon  Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) [PDF, 62 kB]

Federal Joint Committee (G-BA)

2012-03-29 A G-BA decision was published.

G-BA documents on this decision (German only)

Press releases

2012-01-02 Added benefit of linagliptin is not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close